Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B

Breast Cancer

Volumn 20, Issue 2, 2013, Pages 131-136

  Hayashi, Hidetoshi ^a   Tsurutani, Junji ^a   Satoh, Taro ^a   Masuda, Norikazu ^b   Okamoto, Wataru ^a   Morinaga, Ryotaro ^a   Terashima, Masaaki ^a   Miyazaki, Masaki ^a   Okamoto, Isamu ^a   Nishida, Yukihiro ^c   Tominaga, Shusei ^c   Tokunaga, Yukihiko ^d   Yamaguchi, Masahide ^e   Sakamoto, Junichi ^f   Nakayama, Takahiro ^g   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

^c Higashiosaka City General Hospital   (Japan)

^d Osaka Kita Post and Telecom Hosp   (Japan)

^e MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^f NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

HER2 negative; Irinotecan; Metastatic breast cancer; Phase II trial; Topoisomerase I inhibitor

Indexed keywords

ANTHRACYCLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IRINOTECAN; TAXANE DERIVATIVE; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; DRUG DERIVATIVE;

ADULT; AGED; ANOREXIA; ARTICLE; BREAST METASTASIS; CANCER CONTROL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT OUTCOME; VOMITING; BONE TUMOR; BREAST TUMOR; CANCER STAGING; DRUG EFFECT; DRUG RESISTANCE; INTRAVENOUS DRUG ADMINISTRATION; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY;

ADULT; AGED; BONE NEOPLASMS; BREAST NEOPLASMS; CAMPTOTHECIN; DRUG RESISTANCE, NEOPLASM; FEASIBILITY STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; SALVAGE THERAPY; TOPOISOMERASE INHIBITORS; YOUNG ADULT;

EID: 84884801999     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-011-0316-z     Document Type: Article

References (16)

1. Hamilton A, Hortobagyi G. Chemotherapy: what progress in the last 5 years? J Clin Oncol. 2005;23(8):1760-75. (Pubitemid 46211428)
2. Mincey BA, Perez EA. Advances in screening, diagnosis, and treatment of breast cancer. Mayo Clin Proc. 2004;79(6):810-6. (Pubitemid 38691834)
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92. (Pubitemid 32222155)
4. Taguchi T, Tominaga T, Ogawa M, Ishida T, Morimoto K, Ogawa N. A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. CPT-11 Study Group on Breast Cancer. Gan To Kagaku Ryoho. 1994;21(7):1017-24. (Pubitemid 24225028)
5. Taguchi T, Yoshida Y, Izuo M, Ishida T, Ogawa M, Nakao I, et al. [An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with advanced breast cancer]. Gan To Kagaku Ryoho. 1994;21(1):83-90. (Pubitemid 24059454)
6. Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, et al. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol. 2004;22(14):2849-55. (Pubitemid 41079903)
7. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914-23.
8. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001;92(7):1759-68. (Pubitemid 32952493)
9. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17(2):485-93. (Pubitemid 29075232)
10. Fumoleau P, Largillier R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004;40(4):536-42. (Pubitemid 38220770)
11. Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kolbl H, Janicke F, et al. Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol. 2003;14(8):1227-33. (Pubitemid 37039048)
12. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol. 1993;11(5):909-13. (Pubitemid 23146086)
13. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60(24):6921-6. (Pubitemid 32059164)
14. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22(8):1382-8. (Pubitemid 41103619)
15. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol. 2002;62(3):608-17. (Pubitemid 36329379)
16. Fujita K, Sasaki Y. Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007;8(6):554-62. (Pubitemid 47209095)